Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) are currently up over 20.6% after the company released positive results from its Spectra trial. The Spectra trial evaluates 4D-150 in patients with ...
The MarketWatch News Department was not involved in the creation of this content. -- 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level -- ...
4D-150 shows significant reduction in injection burden for wet AMD, with promising durability and tolerability in ongoing clinical trials. 4D Molecular Therapeutics has released positive interim ...
(RTTNews) - Shares of 4D Molecular Therapeutics (FDMT) are up over 26% to $5.69 in premarket trading Friday, following positive 60-week data from its Phase II SPECTRA trial. The SPECTRA trial is ...
Initial interim landmark data analysis (N=50 at 24 Weeks) to be presented by Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial ...
On Saturday, 4D Molecular Therapeutics (NASDAQ:FDMT) announced initial interim 52-week data from the Phase 2b Population Extension cohort of the PRISM trial of 4D-150 in a broad wet age-related ...
4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level 4D-150 demonstrated durable and dose-dependent clinical activity with sustained gains in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback